New York, 05/23/24 – Intelisci, a leading specialist Search and Consulting firm for the biotech industry, is excited to announce the strategic appointment of Sara Cortese to its Scientific Advisory Board. With over 20 years of pharmaceutical R&D experience, Sara brings a wealth of knowledge across AI-driven drug discovery, strategic consulting, and innovative therapeutic development.
Intelisci, known for securing top leaders and subject matter experts to drive innovation in drug and platform development, is committed to supporting emerging biotech companies with simple, transparent, and flexible recruitment solutions. The addition of Sara to the Scientific Advisory Board enhances the unique value Intelisci offers through the insights and guidance of industry experts.
Sara Cortese currently serves as President of SwipeRightBio-tech, where she advises startups, biotech companies, and venture capitals on discovery and development strategies, startup investments, and biotech partnerships. Her impressive career includes roles such as Managing Director at Accenture’s Life Sciences R&D, where she co-developed an AI-driven personalized medicine solution, and co-founder of 1859.ai, a startup microfluidic platform advancing AI in drug discovery. Additionally, she has held significant leadership positions at GSK and Roche, where she was instrumental in the delivery of novel therapeutics and innovations across multiple therapeutic areas and modalities.
Sara has a deep commitment to people and organizational development. She has excelled in building diverse teams tailored to strengths and business needs, mentoring high-potential but inexperienced talent, and fostering collaboration between technical, engineering, AI specialists, and biology-focused professionals. Her current projects include outlining articles that explore the untapped or undervalued potential of experienced women in life sciences, along with other pressing issues in the field.
"We are honored to welcome Sara Cortese to our Scientific Advisory Board," said Matt Tong, Intelisci CEO. "Her extensive experience, particularly in AI and drug discovery, coupled with her strategic vision and innovative approach, will be invaluable as we continue to drive innovation in the biotech sector. Sara’s appointment is strategic in helping Intelisci meet the inflection of AI in drug development, upskilling our knowledge, expanding our networks, and enhancing our ability to consult clients effectively."
Sara is known for her visionary strategic thinking, team-building skills, and commitment to equity, diversity, and inclusion in biotech. Her appointment reflects Intelisci's dedication to providing unparalleled support to biotech companies through the insights and expertise of industry leaders.
For more information about Intelisci and its services, please visit www.intelisci.com
About Intelisci
Intelisci is a specialist executive recruitment and consulting firm dedicated to supporting lean biotech companies in finding leaders and subject matter experts to drive innovation throughout drug and platform development. With simple, transparent, and flexible solutions, Intelisci adds unique value to emerging biotech companies through its Scientific Advisory Board of industry experts.
Comments